PL2654783T3 - Rekombinowane Mycobacterium jako szczepionka - Google Patents

Rekombinowane Mycobacterium jako szczepionka

Info

Publication number
PL2654783T3
PL2654783T3 PL11811539T PL11811539T PL2654783T3 PL 2654783 T3 PL2654783 T3 PL 2654783T3 PL 11811539 T PL11811539 T PL 11811539T PL 11811539 T PL11811539 T PL 11811539T PL 2654783 T3 PL2654783 T3 PL 2654783T3
Authority
PL
Poland
Prior art keywords
vaccine
recombinant mycobacterium
mycobacterium
recombinant
Prior art date
Application number
PL11811539T
Other languages
English (en)
Inventor
Christiane Desel
Stefan H. E. Kaufmann
Silke Bandermann
Leander Grode
Original Assignee
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.
Vakzine Projekt Management Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V., Vakzine Projekt Management Gmbh filed Critical MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.
Publication of PL2654783T3 publication Critical patent/PL2654783T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/35—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Mycobacteriaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
PL11811539T 2010-12-21 2011-12-21 Rekombinowane Mycobacterium jako szczepionka PL2654783T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061425442P 2010-12-21 2010-12-21
US201161436305P 2011-01-26 2011-01-26

Publications (1)

Publication Number Publication Date
PL2654783T3 true PL2654783T3 (pl) 2017-08-31

Family

ID=45529047

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11811539T PL2654783T3 (pl) 2010-12-21 2011-12-21 Rekombinowane Mycobacterium jako szczepionka

Country Status (25)

Country Link
US (2) US9328350B2 (pl)
EP (1) EP2654783B1 (pl)
JP (1) JP6006909B2 (pl)
KR (1) KR101832019B1 (pl)
CN (2) CN108434448A (pl)
AU (1) AU2011347268B8 (pl)
BR (1) BR112013015882B8 (pl)
CA (1) CA2822716C (pl)
CY (1) CY1118539T1 (pl)
DK (1) DK2654783T3 (pl)
EA (1) EA028924B1 (pl)
ES (1) ES2612777T3 (pl)
HK (1) HK1256627A1 (pl)
HR (1) HRP20161623T1 (pl)
HU (1) HUE032866T2 (pl)
LT (1) LT2654783T (pl)
MX (1) MX345575B (pl)
PH (1) PH12013501349B1 (pl)
PL (1) PL2654783T3 (pl)
PT (1) PT2654783T (pl)
SG (2) SG10201808644PA (pl)
SI (1) SI2654783T1 (pl)
SM (2) SMT201700046T1 (pl)
WO (1) WO2012085101A1 (pl)
ZA (1) ZA201304872B (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2654783T3 (pl) * 2010-12-21 2017-08-31 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Rekombinowane Mycobacterium jako szczepionka
EP3090757A1 (en) * 2015-05-04 2016-11-09 Vakzine Projekt Management GmbH Recombinant mycobacterium as an immunotherapeutic agent for the treatment of cancer
KR102317403B1 (ko) * 2019-01-28 2021-10-29 주식회사 바이오앱 당화된 Ag85A 단백질을 포함하는 결핵 예방용 백신 조성물 및 이의 제조방법
CN110499324A (zh) * 2019-09-02 2019-11-26 中生康元生物科技(北京)有限公司 一种用于鉴定肿瘤新抗原的细菌表达载体及筛选鉴定肿瘤新抗原的方法
WO2021228768A1 (en) 2020-05-11 2021-11-18 Vakzine Projekt Management Gmbh Prevention of infectious diseases by modulating the immune system
WO2021228363A1 (en) 2020-05-11 2021-11-18 Vakzine Projekt Management Gmbh Prevention of infectious diseases by modulating the immune system
EP4122491A1 (en) 2021-07-22 2023-01-25 Vakzine Projekt Management GmbH Recombinant microbacterium as an immunotherapeutic agent for the second-line therapy of bladder carcinoma
IL310225A (en) 2021-07-22 2024-03-01 Serum Life Science Europe Gmbh Recombinant MYCOBACTERIUM as an immunotherapeutic agent for the second-line treatment of bladder carcinoma

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2010A (en) * 1873-01-25 James A. House Improvements on sewing machines
AUPO761697A0 (en) 1997-06-30 1997-07-24 Cardiac Crc Nominees Pty Limited Process for the purification of polyethers
EP0902086A1 (en) * 1997-08-22 1999-03-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tuberculosis vaccine
US6776993B2 (en) * 2000-02-22 2004-08-17 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Tuberculosis vaccine
US6471967B1 (en) * 2000-04-17 2002-10-29 The Regents Of The University Of California Recombinant intracellular pathogen vaccines and methods for use
CA2523084C (en) 2003-04-23 2012-09-04 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Tuberculosis vaccine with improved efficacy
EP1649869A1 (en) 2004-10-21 2006-04-26 Vakzine Projekt Management GmbH Combination of a recombinant mycobacterium and a biologically active agent as a vaccine
GB0500102D0 (en) * 2005-01-05 2005-02-09 Isis Innovation Method for generating a memory t cell response
EA026661B1 (ru) * 2010-09-20 2017-05-31 Вакцине Проект Менеджмент Гмбх Вакцина и способ вакцинации против туберкулеза
PL2654783T3 (pl) * 2010-12-21 2017-08-31 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Rekombinowane Mycobacterium jako szczepionka

Also Published As

Publication number Publication date
HRP20161623T1 (hr) 2017-01-27
ZA201304872B (en) 2014-03-26
DK2654783T3 (en) 2017-01-23
CN103354747A (zh) 2013-10-16
EP2654783A1 (en) 2013-10-30
US9328350B2 (en) 2016-05-03
SMT201700046B (it) 2017-03-08
KR20140021534A (ko) 2014-02-20
MX2013007252A (es) 2013-11-04
SG10201808644PA (en) 2018-11-29
ES2612777T3 (es) 2017-05-18
HK1256627A1 (zh) 2019-09-27
SG191332A1 (en) 2013-07-31
WO2012085101A1 (en) 2012-06-28
PH12013501349B1 (en) 2018-09-28
US20160184419A1 (en) 2016-06-30
SMT201700046T1 (it) 2017-03-08
AU2011347268B8 (en) 2016-12-15
JP6006909B2 (ja) 2016-10-12
PT2654783T (pt) 2016-11-08
JP2014501747A (ja) 2014-01-23
US9879268B2 (en) 2018-01-30
AU2011347268A8 (en) 2016-12-15
PH12013501349A1 (en) 2013-08-28
CN108434448A (zh) 2018-08-24
EP2654783B1 (en) 2016-10-05
AU2011347268A1 (en) 2013-07-25
US20130337011A1 (en) 2013-12-19
LT2654783T (lt) 2016-11-25
MX345575B (es) 2017-02-03
SI2654783T1 (sl) 2017-02-28
BR112013015882B8 (pt) 2021-01-05
CA2822716A1 (en) 2012-06-28
HUE032866T2 (en) 2017-11-28
EA201300733A1 (ru) 2013-12-30
KR101832019B1 (ko) 2018-02-23
CY1118539T1 (el) 2017-07-12
EA028924B1 (ru) 2018-01-31
AU2011347268B2 (en) 2016-09-29
BR112013015882B1 (pt) 2020-12-08
CA2822716C (en) 2019-12-03
BR112013015882A2 (pt) 2016-10-04

Similar Documents

Publication Publication Date Title
SG11201400432VA (en) Polypeptide vaccine
GB201005005D0 (en) New vaccine
DK3170508T3 (da) Vaccineformuleringer
BR112013017629A2 (pt) laminina-521 recombinante
DK3023106T3 (da) Mycobacterium-antigensammensætning
EP4109570C0 (en) LIGHT EMITTING DIODE
BR112012031837A2 (pt) triazolopiridinas substituídas
ZA201300395B (en) Influenza vaccine
BR112014005756A2 (pt) vacina
IL222228A0 (en) Hiv vaccine
DK2613999T3 (da) Drev
SMT201700046B (it) Micobatterio ricombinante come vaccino
DE112012002915A5 (de) Ausrückeinrichtung
BR112015010944A2 (pt) acionador mecânico
GB201119999D0 (en) Vaccine
GB201014965D0 (en) Vaccine
DK2748612T3 (da) Forbedret vaccinediagnostik
LT3360569T (lt) Rekombinantinė mikobakterija, kaip vakcina skirta naudoti žmonėms
GB201013006D0 (en) Vaccine
GB201006324D0 (en) Vaccine
GB201120000D0 (en) Vaccine
ZA201302154B (en) Vaccine
FI20115368A0 (fi) Savupiippu
GB201009277D0 (en) Novel vaccine
GB201109294D0 (en) Novel vaccine